Screener
Spyre Therapeutics, Inc. SYRE Other, net
Other, net at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.
The source filing: Spyre Therapeutics, Inc.’s 10-K, filed February 19, 2026.
- Filed
- Feb 19, 2026, 4:01 PM EST
- Fiscal year
- FY2025
- Accession
- 0001636282-26-000020
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Proceeds from issuance of common stock in connection with private placement, net of placement and other offering costs | — | — | 84,555 |
| Payment of contingent value rights liability | (5,251) | (1,430) | (5,786) |
| Proceeds from employee stock option exercises and employee stock plan purchases | 3,306 | 7,511 | 405 |
| Other financing cash flows | — | 1 | (16) |
| Net cash provided by financing activities | 309,025 | 410,906 | 361,077 |
| Effect of exchange rate on cash, cash equivalents, and restricted cash | — | (3) | 25 |
| NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | (3,702) | (99,792) | 152,799 |
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Spyre Therapeutics, Inc.'s other, net?
- Spyre Therapeutics, Inc. (SYRE) reported other, net of $0 in Q4 2025.
- How has Spyre Therapeutics, Inc.'s other, net changed year-over-year?
- Spyre Therapeutics, Inc.'s other, net decreased by 100.0% year-over-year, from $250 to $0.
- What is the long-term trend for Spyre Therapeutics, Inc.'s other, net?
- Over 2 years (2023 to 2025), Spyre Therapeutics, Inc.'s other, net has grown at a -100.0% compound annual growth rate (CAGR), from -$16K to $0.
- What does other, net mean?
- Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.
Ask your AI about Spyre Therapeutics, Inc.'s other, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude